Researchers at Boston University developed a directed differentiation protocol to produce induced pluripotent stem cells (iPSC)-derived mesenchyme-free human intestinal organoids (HIOs) and used them to create cystic fibrosis patient-derived iPSC-derived organoids for the study of disease-causing mechanisms.
Skip to main content
